Omeros’ (OMER) “Buy” Rating Reiterated at D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s target price would indicate a potential upside of 125.45% from the company’s current price.

Several other equities analysts also recently weighed in on OMER. WBB Securities restated a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $33.67.

Omeros Trading Up 82.5%

Shares of NASDAQ OMER traded up $7.22 during trading hours on Wednesday, reaching $15.97. The stock had a trading volume of 16,043,196 shares, compared to its average volume of 1,678,645. The firm has a 50-day moving average of $8.71 and a 200-day moving average of $5.59. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -7.87 and a beta of 2.48. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $17.65.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. On average, equities analysts predict that Omeros will post -3.09 EPS for the current year.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently bought and sold shares of OMER. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros during the second quarter worth approximately $32,000. Harbour Investments Inc. boosted its holdings in Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,251 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Omeros in the 2nd quarter valued at approximately $40,000. Finally, Russell Investments Group Ltd. grew its position in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 5,677 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.